Latest LB Pharmaceuticals News & Updates

See the latest news and media coverage for LB. We track all announcements, press releases, and industry mentions in real time, all in one place.

LB Pharmaceuticals (LB)

Neuromedicines company developing therapies for brain disorders

lbpharma.com

Founded year: 2015
Company type: Private company
Number of employees: 59–200
Industry: Pharmaceuticals

Last updated October 15

Latest news about LB Pharmaceuticals (LB)

In short: LB Pharmaceuticals advanced LB-102 toward 2027 Phase 3 data and announced a $150 million placement

Company announcements

August 11 LB

LB Pharmaceuticals announces Q2 2026 results and corporate update

The company reported a net loss of $51.6 million for Q2, with cash of $327.8 million, and expects topline data from NOVA-2 in H1 2027.

July 29 LB

LB Pharmaceuticals announces $150 million private placement

The funding will support pipeline expansion of LB-102 into new indications and for working capital.

May 12 LB

LB Pharmaceuticals reports Q1 2026 financial results

Initiated pivotal Phase 3 NOVA-2 trial in schizophrenia and Phase 2 ILLUMINATE-1 trial in bipolar depression, with $365.6 million cash.

March 26 LB

LB Pharmaceuticals reports 2025 financial results and corporate update

Positive Phase 2 results for LB-102 in schizophrenia were reported, and Phase 3 NOVA-2 trial and Phase 2 ILLUMINATE-1 trial were initiated. Cash runway extended into Q2 2029.

Media coverage

October 15 Psychiatric Times

LB Pharmaceuticals PIPE | Leerink Partners

View transactions across the Leerink Partners portfolio, filtered by products and sectors.

Never miss news about LB

Track LB and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

LB competitors & trending companies

Browse news for competitors to LB and other trending companies.